N-Zyme Biomedical seeks to provide a much-needed treatment for the millions of people in the US and worldwide that suffer from LPR.
» What is LPR?Our cutting-edge research demonstrates fosamprenavir binds to and inhibits pepsin, preventing pepsin-mediated inflammation and tissue damage.
» Our ResearchFounded by Franco Vigile, an entrepreneur and Nikki Johnston, Ph.D., who dedicated her career to LPR research.
We bring together industry experts from the business, science and medical communities that are working together to create revolutionary treatments for individuals suffering with reflux disorders such as Laryngopharyngeal Reflux (LPR).
Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.